Nasdaq
$2.50▲ 0.81%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $90.6MShares out 36.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.16After-hours26.10.17 06:168-KKey event
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals has scheduled its 2026 Annual Meeting of Stockholders for December 17, 2026. The deadline for submitting stockholder proposals and director nominations is set for October 25, 2026, with a record date of October 28, 2026.…more
$2.50+0.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 06:008-KKey event
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals' subsidiary, NRx Defense Systems, has been awarded an $11.18 million contract by DARPA to conduct the SPARC-TMS clinical trial. This trial evaluates the combination of the drug NRX-101 and robotic transcranial magnetic stimulation for treatment-resistant depression, with patient enrollment set to begin following FDA approval.…more
$2.50+0.81%vs prev closeView filingShare - 9.16Pre-market26.09.16 10:17filed8-KKey event
NRX Pharmaceuticals, Inc.
NRx Pharmaceuticals announced that the FDA has reclassified the amendment to its Abbreviated New Drug Application (ANDA) for preservative-free ketamine from a 'Major Amendment' to a 'Minor Amendment.' Consequently, the FDA's GDUFA goal date for the application has been revised to November 10, 2026.…more
$2.50+0.81%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:30#●●●#●●●
NRx Pharmaceuticals Completes Manufacturing Validation for Preservative-Free Ketamine…more
NRx Pharmaceuticals has completed the required manufacturing process validation and stability testing for its preservative-free ketamine. The company is now positioned to supply the product pending final FDA ANDA approval.…more
$2.50+0.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.15Pre-market26.10.15 21:27
●●●●●●●● ●●●●● ●●●●●●
NRx Pharmaceuticals has received a discipline review letter from the FDA requesting minor labeling changes for its preservative-free ketamine product. The company is currently finalizing requirements to meet the November 10, 2026, GDUFA goal date.…more
$2.50+0.81%vs prev close - 9.30Pre-market26.09.30 20:00
●●●●●●●● ●●●●● ●●●●●●
NRx Pharmaceuticals' subsidiary has secured an $11 million contract from DARPA to evaluate the NRX-101 drug for treatment-resistant depression. While the study aims to serve as a potential FDA registration trial, it remains in the early stages of clinical evaluation.…more
$2.50+0.81%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report